Latham & Watkins Advises Amneal Pharmaceuticals in Acquisition of German Generic Pharmaceuticals Platform

Corporate team advises seventh largest generics firm in prescriptions dispensed on acquisition of German generic products company.

June 13, 2014

Latham & Watkins advised Amneal Pharmaceuticals Holding GmbH, a subsidiary of Amneal Pharmaceuticals LLC – the seventh largest generic pharmaceutical company in the U.S. – in the acquisition of all shares in bioeq pharma GmbH, which provides generic medicinal products for the German pharmaceutical market, from Farmaprojects S.A.U. 

Amneal Pharmaceuticals LLC, headquartered in Bridgewater, New Jersey, develops, manufactures and distributes generic pharmaceutical products and is currently the seventh largest U.S. generics manufacturer in number of prescriptions. It is one of the fastest growing generic pharmaceutical companies and is expanding internationally with global operations in Switzerland, UK, Ireland, India, Spain, Denmark, Germany and Australia. 

The Latham & Watkins corporate team spanned the firm’s German and Spanish offices and comprised partner Harald Selzner in Düsseldorf, partner Ignacio Pallarés in Madrid and partner Christoph Engeler in Hamburg, counsel Christian Engelhardt in Hamburg, with associates Natalie Daghles in Düsseldorf and Ignacio Domínguez in Madrid.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.